Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

Excerpt from the Press Release:

LEXINGTON, Mass., June 15, 2023 /PRNewswire/ — Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced it will present data at the American Headache Society 65^th Annual Meeting, being held from June 15^th through 18^th both virtually and in-person at the J.W. Marriott in Austin, Texas.

The poster showcases data from the Phase 1 study of PUR3100, an orally inhaled dihydroergotamine (DHE) engineered with iSPERSE™ for the treatment of acute migraine in 26 subjects, ages 18-49 years. 

Information on the poster session is as follows:

Title: “A Phase 1 Study to Assess Safety, Tolerability, and Pharmacokinetics of PUR3100, Novel Dry Powder Formulation of DHE for Oral Inhalation, in Healthy Adults”
Poster number: P-05
Poster available for viewing:  from Thursday, June 15^th, 4:00 pm (Central Time)
Attended poster session:  Friday, June 16^th, 12:35 – 1:50 pm (Central Time)

View the poster here on the Pulmatrix website.

The Phase 1 trial was a randomized, double-dummy, double-blinded design to assesses the safety, tolerability, and pharmacokinetics (PK) of three dose groups of inhaled PUR3100 with intravenous (IV) placebo, compared to a single dose of IV DHE (DHE mesylate injection) with inhaled placebo. PUR3100 was generally well tolerated with fewer TEAEs in PUR3100-treated groups than in the IV DHE-treated group.

Click the button below to read the entire Press Release:

Continue Reading The Press Release